Document is current
Any future updates will be listed below
-
Authors
Kelley, Kristen C.
Grossman, Kenneth F.
Brittain-Blankenship, Mary
Thorne, Kelli M.
Akerley, Wallace L.
Terrazas, Moises C.
Kosak, Ken M.
Boucher, Kenneth M.
Buys, Saundra S.
McGregor, Kimberly A.
Werner, Theresa L.
Agarwal, Neeraj
Weis, John R.
Sharma, Sunil
Ward, John H.
Kennedy, Thomas P.
Sborov, Douglas W.
Shami, Paul J.
- License Information
-
More Information
Article History
Received: 16 December 2020
Accepted: 15 April 2021
First Online: 7 May 2021
Declarations
:
: The study was conducted under Investigational New Drug (IND) #100,937 and approved by the University of Utah Institutional Review Board. Informed consent was obtained from all participants. All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: PJS: co-founder, shareholder, and Chief Medical Officer in JSK Therapeutics. Co-founder and shareholder in Lone Star Thiotherapies. Research funding from Cantex Pharmaceuticals, Chimerix, Amgen, Aptevo, Ono, and Pfizer. Consultancy with BMS, Gilead, and Takeda. TPK: co-founder, shareholder in JSK Therapeutics, Lone Star Thiotherapies, and Cantex Pharmaceuticals. DWS: advisor and consultant to Janssen, Skyline Dx, GlaxoSmithKline, Legend Biotech, Amgen, and Celgene. NA: Consultant to Astellas, Astra Zeneca, Bayer, Bristol Myers Squibb, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. Institutional research funding has been provided by Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Glaxo Smith Kline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. The remaining authors have no relevant disclosures.
